Executive search firm Toft Group has placed Julia P. Gregory as Non-Executive Director and Audit Chair of Board of Directors for Cell Medica in Houston, TX.
Ms. Gregory has extensive experience in senior roles in the biopharmaceutical industry as well as more than 20 years of investment banking experience. She currently serves as a non-executive director of several biopharmaceutical companies, including Sosei Group Corporation and Biohaven Pharmaceuticals. Ms. Gregory is also Chairman and CEO of the biotechnology financial and management advisory firm Isometry Advisors, Inc.
In her previous executive roles, Ms. Gregory served as Chief Executive Officer, Chief Financial Officer and Board Director of ContraFect Corporation; President and CEO of Five Prime Therapeutics; and Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Her corporate development experience includes leading transactions with GlaxoSmithKline, Human Genome Sciences, Genentech, Bristol-Myers Squibb Company and Takeda Pharmaceutical.
Prior to working in the biopharmaceutical industry, Ms. Gregory was an investment banker. Ms. Gregory has also served on the Board of Directors at The Global TB Alliance for Drug Development, Clinipace Worldwide, and the Institute for the Study of Aging, a private foundation for Alzheimer’s.
Ms. Gregory holds an MBA from the Wharton School at the University of Pennsylvania and a BA from George Washington University.
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.
About Cell Medica
Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Cell Medica’s lead product is CMD-003 and is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. Cell Medica is working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR- modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, they are collaborating with University College London to develop the Dominant TCR technology platform.
Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.